BioSpace News Archive

Nymox Pharmaceutical Corporation is pleased to provide a current update on business developments.

The global Augmented and Virtual Reality in Healthcare market size was estimated at USD 2.3 billion in 2021 and is expected to surpass around USD 19.6 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 26.88% during the forecast period 2022 to 2030.

Nextech, the market leader in electronic health record and practice management software for ophthalmology, dermatology, plastic surgery, and other specialty practices, is pleased to announce that the functionality required by the 21st Century Cures Act and Merit-Based Incentive Payment System attestation compliance will be available for all Nextech clients in advance of the requirements defined by the Cures Act legislation.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, is pleased to announce its participation in the 46th Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference & Exhibit at the Palm Beach County Convention Center in West Palm Beach, Florida on September 15 – 17, 2022.

Prolifagen Therapeutics, a biotech startup developing medicines for cardiac regeneration, has appointed M. Alexander Shaw, PhD, as Chief Executive Officer.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc.

Aqua-Yield, the leading nanoliquid company for agricultural production worldwide, today announced the close of its Series A investment round of $23M.

The 3D cell culture market is seeing a steady development because of the elements, as tremendous ventures by life science organizations for R&D, advancement of robotized enormous scale cell culture frameworks, and rising requirement for organ replacement.

Natural killer cells are generally big granular lymphocytes. These cells react quickly to any pathological problem.

RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bringing its cumulative financing to over $25 million.